Pediatric Cardiology

Top Story

HYDRA: Rosuvastatin reduces LDL in children with homozygous FH

HYDRA: Rosuvastatin reduces LDL in children with homozygous FH
August 21, 2017

Children with homozygous familial hypercholesterolemia who were treated with rosuvastatin in addition to ezetimibe and/or apheresis reduced their LDL safely and effectively, according to a randomized, double blind crossover study published in the Journal of the American College of Cardiology.

Evan A. Stein, MD, PhD, director emeritus of the Metabolic and Atherosclerosis Research Center in Cincinnati, and colleagues analyzed data from 14 children (mean age, 11 years; 50% boys) with homozygous familial hypercholesterolemia (HoFH), 13 of whom completed the HYDRA study. A 4-week lead-in phase preceded the study, when patients discontinued all lipid-lowering therapies except apheresis (50%) and/or ezetimibe (57%) and received 10 mg rosuvastatin daily with dietary advice.

Boston Children’s to join Cleveland Clinic network

August 19, 2017
Boston Children’s Hospital and Cleveland Clinic have entered into an agreement to provide complex pediatric heart services through Cleveland Clinic’s…
In the Journals

Lower socioeconomic status may lead to thicker artery walls in children

August 9, 2017
Lower socioeconomic status in early childhood was associated with an increase in carotid intima-media thickness at age 11 to 12 years, according to recent findings. …
In the Journals

Arterial distensibility in adolescence tied to CV risk factors

August 4, 2017
Risk factors such as BP, BMI, LDL and insulin resistance were linked to arterial distensibility in adolescence, according to a study published in Hypertension
More Headlines »
Advertisement
Advertisement